Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

(2019) Sigbjørn Smeland et al.   EUROPEAN JOURNAL OF CANCER

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

(2019) Ryan D. Roberts et al.   CANCER

Panobinostat mediated cell death. A novel therapeutic approach for osteosarcoma

(2018) André Wirries et al.   Oncotarget

HDAC2 depletion promotes osteosarcoma’s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy

(2018) Marcella La Noce et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations

(2018) Amos H.P. Loh et al.   CANCER LETTERS

Orthotopic patient-derived xenografts of paediatric solid tumours

(2017) Elizabeth Stewart et al.   NATURE

Re-calculating! Navigating through the osteosarcoma treatment roadblock

(2017) J. McGuire et al.   PHARMACOLOGICAL RESEARCH

Exploring genomic alteration in pediatric cancer using ProteinPaint

(2016) Xin Zhou et al.   NATURE GENETICS

HDACs and HDAC Inhibitors in Cancer Development and Therapy

(2016) Yixuan Li et al.   Cold Spring Harbor Perspectives in Medicine

Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells

(2015) KOJI YAMANEGI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Panobinostat Approved for Multiple Myeloma

(2015)   Cancer Discovery

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

(2015) Diana Yu et al.   Scientific Reports

The HDAC Inhibitor Vorinostat Diminishes theIn VitroMetastatic Behavior of Osteosarcoma Cells

(2015) Xiaodong Mu et al.   Biomed Research International

Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer

(2014) Xiaoyang Li et al.   CURRENT DRUG TARGETS

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

Osteosarcoma treatment – Where do we stand? A state of the art review

(2013) Anja Luetke et al.   CANCER TREATMENT REVIEWS

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity

(2013) David M. Woods et al.   MELANOMA RESEARCH

Extraskeletal Osteosarcoma: Spectrum of Imaging Findings

(2011) Grainne Mc Auley et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma

(2011) Luke A. Wittenburg et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases

(2009) A. H. Aljubran et al.   ANNALS OF ONCOLOGY

Molecular Characterization of the Pediatric Preclinical Testing Panel

(2008) G. Neale et al.   CLINICAL CANCER RESEARCH